GlobeNewswire: Vascular Biogenics Ltd. Contains the last 10 of 165 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:21:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/10/12/2759289/0/en/VBL-Therapeutics-Announces-Results-of-Annual-and-Special-Shareholder-Meeting.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting2023-10-12T13:00:00Z<![CDATA[Approved Merger with Notable Labs and All Other Proposals]]>https://www.globenewswire.com/news-release/2023/10/04/2754511/0/en/VBL-Therapeutics-Reminds-Shareholders-to-Vote-in-the-Upcoming-Annual-and-Special-Shareholder-Meeting.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting2023-10-04T12:00:00Z<![CDATA[Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023]]>https://www.globenewswire.com/news-release/2023/09/06/2738347/0/en/VBL-Therapeutics-Announces-that-S-4-Registration-Statement-for-Proposed-Merger-with-Notable-Labs-Is-Declared-Effective-by-SEC.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC2023-09-06T12:00:00Z<![CDATA[Merger with Notable expected to close in mid-October, subject to shareholder approval]]>https://www.globenewswire.com/news-release/2023/08/14/2724325/0/en/VBL-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update2023-08-14T12:00:00Z<![CDATA[Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval]]>https://www.globenewswire.com/news-release/2023/05/15/2669270/0/en/VBL-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update2023-05-15T20:01:00Z<![CDATA[Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals]]>https://www.globenewswire.com/news-release/2023/03/14/2626587/0/en/VBL-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update2023-03-14T12:00:01Z<![CDATA[MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2023/03/09/2624072/0/en/VBL-Therapeutics-Announces-Closing-of-Sale-of-Manufacturing-Facility-and-Certain-Related-Assets-for-7-1-Million-in-Cash.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash2023-03-09T13:00:00Z<![CDATA[MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company. VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023.]]>https://www.globenewswire.com/news-release/2023/02/23/2614116/0/en/VBL-Therapeutics-and-Notable-Labs-Announce-Definitive-Merger-Agreement.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement2023-02-23T12:00:00Z<![CDATA[Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”)]]>https://www.globenewswire.com/news-release/2023/02/16/2609663/0/en/VBL-Therapeutics-Announces-Agreement-to-Sell-Manufacturing-Facility-and-Certain-Related-Assets-for-7-1-Million-in-Cash.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash2023-02-16T13:00:00Z<![CDATA[MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today that it has entered into an agreement to monetize its manufacturing facility in Modiin, Israel and certain related assets, for $7.1 million in cash. VBL also has the right to sell certain equipment excluded from the agreement for additional cash consideration. The asset sale is subject to customary closing conditions and expected to close on or about March 9, 2023.]]>https://www.globenewswire.com/news-release/2022/11/14/2555443/0/en/VBL-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=34600VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update2022-11-14T21:05:00Z<![CDATA[Continued progress on previously announced strategic process to maximize shareholder value Continued progress on previously announced strategic process to maximize shareholder value]]>